Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.71 |
| ▸ | CTSD | P07339 | 9/20 | 0.68 |
| ▸ | CTSB | P07858 | 4/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7893721 | 0.83 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL12747270 | 0.83 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL12747268 | 0.83 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL7888221 | 0.81 | BACE1 (1.00) | BACE1 | |
| SCHEMBL430542 | 0.81 | BACE1 (0.66) | BACE1CTSDCTSBBACE2 | |
| SCHEMBL427887 | 0.81 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL430513 | 0.81 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL428044 | 0.79 | BACE1 (0.63) | BACE1CTSD | |
| SCHEMBL448861 | 0.77 | BACE1 (0.79) | BACE1CTSDCTSB | |
| SCHEMBL429131 | 0.77 | BACE1 (0.79) | BACE1CTSDCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885CTSD 427/4885CTSB 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.